FDA Issues Guidance for Cardiovascular Risk Assessment of Novel Antidiabetic Agents
Cardiovascular disease associated with type 2 diabetes (T2DM) has become a significant concern in the development of new T2DM therapies. The US Food and Drug Administration (FDA) has issued a final guidance for industry on utilizing clinical trials to demonstrate that a new T2DM treatment does not pose an unacceptable increase in the risk of cardiovascular events. The FDA continues to endorse blood glucose control, measured by glycated haemoglobin (HbA1c) levels, as the primary efficacy end point.
With the prevalence of T2DM on the rise, patients face a notably higher risk of heart disease compared to non-diabetics. Currently, no approved antidiabetic agents have been conclusively proven to reduce this risk, and some may even elevate it. Given that T2DM often necessitates lifelong treatment, gathering more information on how T2DM treatments impact cardiovascular events is crucial.
The newly effective guidance outlines a comprehensive approach for collecting, analyzing, and reporting essential safety information from all Phase II and III trials of a novel drug. Clifford Rosen, Director of Clinical and Translational Research at Maine Medical Center and a member of the FDA Endocrinologic and Metabolic Drug Advisory Committee, highlights the significance of these guidelines. "These guidelines represent a major adjustment by the FDA in response to mounting concerns about cardiovascular risk," Rosen states. He emphasizes the establishment of a separate and independent cardiovascular end-point committee to adjudicate cardiovascular events and the inclusion of high-risk individuals, such as the elderly and those with renal impairment, in Phase II and III studies.
Upon trial completion, a meta-analysis of all data is required. Brian Strom, Chair of the Department of Biostatistics and Epidemiology at the University of Pennsylvania School of Medicine, praises this approach. "I think this is an extremely wise, reasoned, balanced, and scientific approach to evaluating the cardiovascular safety of drugs newly developed for use in diabetes," Strom remarks. He notes the importance of the meta-analysis in integrating all available data to make informed judgments on whether additional data are necessary, either premarketing or postmarketing. Rosen also mentions that the guidance includes upper boundaries for confidence intervals to assess increased risk and the need for postmarketing studies.